explore -WSS

explore

author：focus 2025-09-28 07:21:46 - browse：2822

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Lack of health data on LGBTQ+ people has serious consequences

WSS

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Biden's 'march

A new approach to psychiatric drug development

Biden's 'march

For AI in health care standards, federal regulators join with industry group

Microsoft's Peter Lee: Generative AI could help doctors be more human

explore

explore

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Global childhood vaccinations edge closer to pre

What does generative AI mean for health care? We asked experts

Why police arrested suspected Gilgo Beach killer away from his house

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Immune cells and nerve overgrowth may explain recurring UTI pain

Guidelines to prevent youth baseball injuries need more muscle

First over

Peter Hotez and the public health issue of online harassment

Congress likely to miss an opportunity to fix drug shortages issue

focus

For AI in health care standards, federal regulators join with industry group

J&J expands global access to TB drug amid advocacy campaign

Pregnant women don't need prenatal multivitamins, study concludes

Global childhood vaccinations edge closer to pre

Blood tests recalled over risk of missed heart attack diagnosis

Florida health officials providing scant details on measles cases

hotspot

knowledge

Wikipedia

entertainment